Suppressed pediatric asthma hospitalizations during the COVID‐19 pandemic in Japan, from a national survey
Seigo Korematsu,Takao Fujisawa,Naruo Saito,Junichiro Tezuka,Katsushi Miura,Ichiro Kobayashi,Ippei Miyata,Yujiro Kosugi,Yuji Gohda,Yumi Koike,Ami Suda,Akiko Matsuo,Michiyo Sasaki,Yousuke Handa,Michimasa Fujiwara,Atsushi Ono,Shinya Koizumi,Taku Oishi,Takayuki Tanaka,Yusuke Ando,Naohiko Taba,Yuki Tsurinaga,Takeshi Sato,Rei Kanai,Masato Yashiro,Toshiyuki Takagi,Shinya Hida,Masashi Harazaki,Takayuki Hoshina,Seigo Okada,Motoko Yasutomi,Setsuko Nakata,Ayako Muto,Saori Tanabe,Yutaka Ueda,Shunji Hasegawa,Makoto Kameda,Keiko Tanaka‐Taya,Tsuguto Fujimoto,Kenji Okada
DOI: https://doi.org/10.1002/clt2.12330
2024-01-01
Clinical and Translational Allergy
Abstract:Abstract Background Acute asthma exacerbation in children is often caused by respiratory infections. In this study, a coordinated national surveillance system for acute asthma hospitalizations and causative respiratory infections was established. We herein report recent trends in pediatric acute asthma hospitalizations since the COVID‐19 pandemic in Japan. Methods Thirty‐three sentinel hospitals in Japan registered all of their hospitalized pediatric asthma patients and their causal pathogens. The changes in acute asthma hospitalization in children before and after the onset of the COVID‐19 pandemic and whether or not COVID‐19 caused acute asthma exacerbation were investigated. Results From fiscal years 2010–2019, the median number of acute asthma hospitalizations per year was 3524 (2462–4570), but in fiscal years 2020, 2021, and 2022, the numbers were 820, 1,001, and 1,026, respectively (the fiscal year in Japan is April to March). This decrease was observed in all age groups with the exception of the 3‐ to 6‐year group. SARS‐CoV‐2 was evaluated in 2094 patients from fiscal years 2020–2022, but the first positive case was not detected until February 2022. Since then, only 36 of them have been identified with SARS‐CoV‐2, none of which required mechanical ventilation. Influenza, RS virus, and human metapneumovirus infections also decreased in FY 2020. In contrast, 24% of patients had not been receiving long‐term control medications before admission despite the severity of bronchial asthma. Conclusion SARS‐CoV‐2 was hardly detected in children with acute asthma hospitalization during the COVID‐19 pandemic. This result indicated that SARS‐CoV‐2 did not induce acute asthma exacerbation in children. Rather, infection control measures implemented against the pandemic may have consequently reduced other respiratory virus infections and thus acute asthma hospitalizations during this period. However, the fact that many hospitalized patients have not been receiving appropriate long‐term control medications is a major problem that should be addressed.
allergy